34 Lives is dedicated to addressing the critical issue of organ transplantation, particularly focusing on kidney preservation. The company employs innovative technologies such as warm Normothermic preservation, which allows kidneys to remain alive and healthy outside the body for extended periods. This method significantly increases the viability of unused kidneys, enabling more informed decision-making for transplant surgeons and Organ Procurement Organizations (OPOs). By providing detailed assessments and additional data on each kidney, 34 Lives aims to rescue and revive organs that would otherwise go unused, ultimately striving to reduce the number of patients removed from the transplant waiting list.

The leadership team at 34 Lives brings a wealth of experience from various fields, including transplantation, healthcare, and technology. CEO Chris Jaynes has a background in developing equipment for organ assessment, while CCO Kathleen St. Jean has extensive experience in the pharmaceutical industry. The team also includes experts in experimental transplantation surgery and organ preservation, such as Professor Henri Leuvenink and Tom Taccini, who have contributed to advancements in machine perfusion and organ preservation technologies. Together, they are committed to transforming the kidney transplantation process and improving outcomes for patients awaiting life-saving transplants.

United States

Every day in the US, approximately 34 patients are removed from the transplant waiting list either because they die or they become too sick to receive a transplant.

Our mission is to bring that number down to zero by developing innovative technology and services that will extend the safe preservation times for unused kidneys.

34 Lives

Company Details